Lenvatinib plus pembrolizumab for renal cell carcinoma - The authors reply Correspondence

  

Authors:	Motzer, R.; Choueiri, T. K.
Title:	Lenvatinib plus pembrolizumab for renal cell carcinoma - The authors reply
Keywords:	renal cell carcinoma; kidney neoplasms; monoclonal antibody; kidney tumor; carcinoma, renal cell; quinolines; quinoline derivative; antibodies, monoclonal, humanized; phenylurea compounds; lenvatinib; carbanilamide derivative; humans; human; pembrolizumab
Journal Title:	New England Journal of Medicine
Volume:	385
Issue:	3
ISSN:	0028-4793
Publisher:	Massachusetts Medical Society
Date Published:	2021-07-15
Start Page:	287
Language:	English
DOI:	10.1056/NEJMc2107518
PUBMED:	34260846
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112125693&doi=10.1056%2fNEJMc2107518&partnerID=40&md5=50004e46581bea0c6a1722f1e63bef08
Notes:	Letter -- Export Date: 1 September 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/186056